HIV Treatment
Page 1 • 2 itemsGlobal HIV treatment market intelligence: Stay ahead with insights on drug development, regulatory approvals, and investment opportunities.
FDA Grants Priority Review for Gilead's Bictegravir Plus Lenacapavir HIV Treatment Combination
Gilead Sciences receives FDA priority review for novel once-daily HIV treatment combining bictegravir and lenacapavir, potentially the smallest single-tablet regimen.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.